Rmc 4550

Manufactured by MedChemExpress

The RMC-4550 is a precision rotary microtome designed for the sectioning of biological and synthetic samples. It features a high-quality stainless-steel knife holder and a motorized cutting mechanism for accurate and reproducible sectioning.

Automatically generated - may contain errors

Lab products found in correlation

Capivasertib, by MedChemExpress (1 mentions) Mrtx849, by MedChemExpress (1 mentions) C57 b6j mice, by Jackson ImmunoResearch (1 mentions) Nu nu mice, by Inotiv (1 mentions) Shp099, by MedChemExpress (1 mentions)

3 protocols using rmc 4550

Dual MEK and AKT Inhibition in Autochthonous Mouse Tumor Models

Check if the same lab product or an alternative is used in the 5 most similar protocols

For drug efficacy studies in autochthonous mouse models, TC mice (8–12 weeks old) were divided into 4 groups randomly 3.5 months after tumour initiation. They received the vehicle, capivasertib (100 mg/kg, MedChemExpress), RMC-4550 (30 mg/kg, MedChemExpress), or a combination of both dissolved in 10% DMSO, 40% PEG, 5% Tween 80, and 45% PBS through oral gavage. Mice were treated daily for eight days, and the treatment was stopped for two days for recovery, and continued for two more days before the tissue harvest. The last two doses of combination therapy were half of the initial doses.
Cell line-derived allografts were generated through subcutaneous injection of 300,000 of MY-C3 (Nf1, Rasa1, Pten, and Trp53 mutant) oncogene-negative mouse cell line in 200 μl of PBS in male (6–8 week old) BL6 mice (two tumors per mouse). Once tumors reached an average size of ~100 mm³ administration of RMC-4550 (30 mg/kg, MedChemExpress) and capivasertib (100 mg/kg, MedChemExpress) (5 days on, 2 days off) for 17 days.

Yousefi M., Boross G., Weiss C., Murray C.W., Hebert J.D., Cai H., Ashkin E.L., Karmakar S., Andrejka L., Chen L., Wang M., Tsai M.K., Lin W.Y., Li C., Yakhchalian P., Colón C.I., Chew S.K., Chu P., Swanton C., Kunder C.A., Petrov D.A, & Winslow M.M. (2022). Combinatorial inactivation of tumor suppressors efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities. Cancer research, 82(8), 1589-1602.

+ Open protocol

+ Expand

Lung Tumor Xenograft in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols

Eight-week-old female C57B/6J mice were purchased from Jackson Labs (Bar Harbor, ME) and eight-week-old nu/nu mice were purchased from Envigo (Indianapolis, IN). For tumor cell inoculation, parental LLC, LLC 46 NRAS KO, LLC 23 NRAS KO and mKRC.1 cells were grown to 75% confluence, harvested, and resuspended in sterilized phosphate buffered saline. Cells were counted and resuspended to a final concentration of 125,000 cells per 40uL injection. Cell suspensions were directly injected into the left lung of mice through the ribcage. Mice were randomized into groups to receive diluent control, RMC-4550 (30 mg/kg; MedChem Express), MRTX-849 (30 mg/kg; MedChem Express), or the combination by daily oral gavage until primary experimental endpoints were met. Treatment was initiated following confirmation that at least 75% of mice had calculatable primary left lung tumors via microCT imaging (CUD Small Animal Imaging Core). MicroCT imaging was conducted weekly and ITK-SNAP software (26 (link)) was used to calculate cross-sectional tumor volumes in cubic millimeters. Mice exhibiting signs of morbidity according to the guidelines set by the Institutional Animal Care and Use Committee (IACUC) were sacrificed immediately.

Sisler D.J., Hinz T.K., Le A.T., Kleczko E.K., Nemenoff R.A, & Heasley L.E. (2023). Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models. Frontiers in Oncology, 13, 1094123.

+ Open protocol

+ Expand

Chordoma Cell Lines and Small Molecule Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

UM-Chor1, JHC7, MUG-Chor1, U-CH1, and U-CH2 chordoma cell lines were obtained from the Chordoma Foundation. CH22 cells have been described previously in ref. ^{66 (link)} and were obtained from the Chordoma Foundation and Massachusetts General Hospital. MDA-MB-468 breast adenocarcinoma and A2058 melanoma cell lines were obtained from ATCC. UM-Chor1 cells were maintained in IMDM/RPMI (4:1) media + 10% fetal bovine serum (FBS) and 1X non-essential amino acids. JHC7 cells were maintained in DMEM/F12 (1:1) + 10% FBS. MUG-Chor1, U-CH1, and U-CH2 cell lines were maintained in IMDM/RPMI (4:1) media + 10% FBS. CH22 and MDA-MB-468 cells were maintained in RPMI media + 10% FBS. A2058 cells were maintained in DMEM media + 10% FBS. All chordoma cell lines were maintained on collagen I-coated plates.
RMC-4550 and SHP099 were purchased from MedChemExpress. TNO155 used for ex vivo studies was purchased from Selleck Chemicals, and that used for in vivo studies was purchased from MedChemExpress.

Sharifnia T., Wawer M.J., Goodale A., Lee Y., Kazachkova M., Dempster J.M., Muller S., Levy J., Freed D.M., Sommer J., Kalfon J., Vazquez F., Hahn W.C., Root D.E., Clemons P.A, & Schreiber S.L. (2023). Mapping the landscape of genetic dependencies in chordoma. Nature Communications, 14, 1933.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!